Albany Molecular Research Announces Drug Discovery Research Collaboration with Alcon
Albany Molecular Research, Inc. announced that it has entered into a two-year research collaboration with Alcon Research, Ltd. to discover and develop ophthalmic pharmaceuticals. Under the terms of the agreement, AMRI will screen samples from its natural product collections, with the goal of identifying and developing lead compounds with desired biological activity against ophthalmic-related biological targets. Additional AMRI compound collections may also be screened under the agreement. AMRI will also provide custom chemical synthesis services. The contract includes fee-for-service provisions and library access fees, as well as opportunities for AMRI to receive milestone payments based on the achievement of certain development and regulatory benchmarks. In addition, AMRI would receive royalty payments on net sales of commercial products that result from the collaboration.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.